Raymond James reiterates USD 19.00 target for Vir Biotechnology stock

Published on 10/06/2026 at 05:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vir will present hepatitis delta data on November 8, 2026. Eight analysts give Vir Biotechnology stock a USD 21.57 average target in consensus.

VIR, US92764N1028, Illustration mit AI erstellt.

Vir Biotechnology (ISIN US92764N1028) is entering a key clinical-data window after Investing.com reported on September 28, 2026 that Raymond James reiterated a Strong Buy rating and a USD 19.00 price target. Vir Biotechnology stock is also approaching a scheduled data presentation that could sharpen expectations for its hepatitis delta program.

Hepatitis delta data date set

Vir announced on October 5, 2026 that it will present expanded Phase 2 SOLSTICE results for elebsiran and tobevibart at the American Association for the Study of Liver Diseases meeting. The presentations are scheduled for November 8, 2026, in Denver, with one session covering hepatitis delta virus responses through Week 96.

StockTitan reports that the second presentation will examine intrahepatic natural killer cell remodeling in the SOLSTICE trial. The two sessions put clinical durability and immune-response detail at the center of the next company-specific catalyst.

Second-quarter revenue beats consensus

Vir reported USD 238.95 million in revenue for the second quarter of 2026, compared with USD 135.88 million consensus, according to MarketBeat on its Vir earnings summary. Earnings per share reached USD 0.47 versus a USD 0.33 consensus estimate for the same period.

The revenue comparison matters because the quarterly result included a substantial collaboration payment, while the clinical pipeline still determines the companys longer-term value. A revenue figure above consensus can support near-term sentiment, but the November data will provide more direct evidence about the programs clinical progress.

Analyst target remains above market value

Raymond James cited the competitive hepatitis delta landscape when it reiterated its USD 19.00 target on September 28, 2026. The same report said the firm expected Virs tobevibart and elebsiran combination to show a competitive clinical profile, while the market debate would center on the depth of viral suppression and longer-term liver outcomes.

That assessment gives the November presentation a practical test: investors can compare the new Week 96 response detail with the clinical markers analysts use to judge durability. The outcome could influence how the market weighs Virs hepatitis delta opportunity against continued development spending.

Market value and trading context

Vir Biotechnology had a market capitalization of USD 1.9 billion on October 5, 2026. Its Nasdaq 52-week range was USD 4.82 to USD 11.94, placing the company in the small-cap biotechnology segment.